Yiming Liu represents companies and investment funds on strategic transactions in the life sciences and technology industries. Yiming regularly advises clients on the structuring, negotiation and documentation of a wide range of cross-border transactions, including mergers and acquisitions, private equity investments, venture financings, joint ventures, licensing and collaboration arrangements. In addition, Yiming is widely recognized for his work on life sciences and healthcare IPOs in Hong Kong and the US. In particular, he is adept in leading the compilation of offering documents and the communications with issuers, underwriters, investors and regulators during the listing processes. With advanced degrees in molecular, cellular and developmental biology and health services administration, Yiming leverages his technical background to help clients achieve their desired results.

Download full bio 


  • Cryofocus Medtech – HK$210 Million IPO 

  • InnoRNA Collaboration with BeiGene 

  • Asymchem Agrees to Acquire Snapdragon Chemistry 

  • Asymchem Laboratories – HK$7.15 Billion IPO 

  • Keymed Biosciences – HK$3.1 Billion IPO 


  • Columbia University

  • University of Michigan
    MS (molecular, cellular, and developmental biology) , MHSA (health services administration)

  • Fudan University
    BS (biological sciences)

Admissions & Credentials

New York

Hong Kong (Registered Foreign Lawyer)

Rankings & Accolades

    Asian Legal Business (ALB), Thomson Reuters: China Top 15 Capital Markets Lawyers (2022)

    Asian Legal Business (ALB), Thomson Reuters: China Top 15 Rising Lawyers (2022)